Navigation Links
Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
Date:10/24/2009

>Contrave Obesity Research (COR) Trial Design and Safety Profile

All Phase 3 trials in the COR program were 56 week, randomized, double-blind, placebo-controlled trials. The co-primary endpoints were the proportion of patients achieving at least 5% weight loss and percent change in body weight compared to placebo. Secondary endpoints included multiple markers of cardiometabolic risk, patient reported food cravings and eating control measures, as well as HbA1c in the COR-Diabetes trial. Patients were randomized to receive either placebo or Contrave, BID, with a four week titration period.

As previously reported, seven serious adverse events were attributed by investigators as possibly related to Contrave treatment across the entire COR program. These include cholecystitis (gallbladder inflammation), seizure, palpitations, paresthesia and vertigo. The most frequently observed treatment-emergent adverse events were nausea, constipation and headache. Nausea was the leading adverse event resulting in discontinuation; however, for the majority of patients experiencing nausea, it was mild to moderate, transient and manageable.

At week 56, mean blood pressure was generally unchanged from baseline for Contrave patients compared to placebo patients, who tended to experience a slight decrease (approximately 2 mm Hg) from baseline. Contrave treatment did not appear to disrupt the normal circadian pattern of blood pressure. There was a slight increase in pulse (approximately 1 beat per minute) in Contrave patients compared to placebo patients, whose pulse was generally unchanged. There were no meaningful treatment effects on ECGs or laboratory measures including liver function tests. Treatment with Contrave was not associated with increases in symptoms of depression or suicidal ideation.

The Company is on track to submit a New Drug Application (NDA) for Contr
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
4. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
5. Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
6. Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock
7. Orexigen(R) Therapeutics Prices Public Offering of Common Stock
8. Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results
9. Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients
10. Prime Therapeutics Receives TIPPS Certification
11. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... research suggests the adage that encourages people to keep ... when it comes to exercise. When walking, staying focused ... to it appear shorter and help people walk there ... this technique to walking while looking around the environment ... of exercise. , "People are less interested in exercise ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog ... plan for vulnerable family members. , Life insurance plans ... in the family should always carry a life insurance ... the rest of the family. , Clients can ... more from temporary coverage or from a permanent policy. ...
(Date:10/1/2014)... First Warning Systems, a pioneer in ... throughout the body, announced the company is changing its ... company’s breadth of upcoming product releases. The initial focus ... , “Our initial focus will be an ‘Internet of ... circadian cellular changes over time,” said Rob Royea, president ...
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
(Date:10/1/2014)... California (PRWEB) October 01, 2014 Beverly ... Dr. Kathleen Mojas is celebrating 20 years of private ... assisted hundreds of people to achieve greater joy and ... important list of warning signs and suggestions for anyone ... Dr. Mojas explains: “Believe it or not, it’s ...
Breaking Medicine News(10 mins):Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3
... patients with cirrhosis have significant functional disability, require twice ... on the health care system, according to U-M research ... increase in obesity and aging of those with hepatitis ... climb among older Americans.. Cirrhosis is a ...
... TUESDAY, Jan. 10 (HealthDay News) -- Asian-Americans are more ... attack than whites, new research reveals, although this disparity ... quality improvement program. In the study, doctors examined ... patient was prescribed aspirin or ACE inhibitors (heart drugs) ...
... shows that older Americans with cirrhosis have significantly worse ... without this potentially deadly disease. In fact, findings now ... the American Association for the Study of Liver Diseases, ... amount of informal caregiving and contribute added strain on ...
... HealthDay Reporter , TUESDAY, Jan. 10 (HealthDay ... early clinical trial of the drug Nexavar (sorafenib) in ... in better news, an experimental drug known as ganetespib ... The results of both studies were to be presented ...
... 10, 2012. Kessler Foundation and the University of ... collaborate on clinical research projects applying virtual reality ... goal, according to USC,s Albert Rizzo, PhD of ... to conduct research to develop the evidence base ...
... Reporter , MONDAY, Jan. 9 (HealthDay News) -- For years, people ... of dying from a heart attack, stroke or cancer even if ... into question. Low-dose daily aspirin therapy does not reduce ... new study in the Jan. 9 online edition of the ...
Cached Medicine News:Health News:High rates of disability and health care use found in older Americans with cirrhosis 2Health News:Asian-Americans More Apt to Die in Hospital After Heart Attacks 2Health News:High rates of disability and health care use for older americans with cirrhosis 2Health News:Mixed News on Tough-to-Treat Lung Cancer 2Health News:Mixed News on Tough-to-Treat Lung Cancer 3Health News:Kessler Foundation and USC collaborate on clinical virtual reality for disability research 2Health News:Low-Dose Aspirin to Prevent First Heart Attack or Stroke? Not So Fast 2Health News:Low-Dose Aspirin to Prevent First Heart Attack or Stroke? Not So Fast 3
(Date:10/1/2014)... 1, 2014  ResMed (NYSE: RMD ), a ... company to design complete sleep apnea solutions specifically for women, ... importance of a good night,s sleep. The ... that feeling tired is just part of living a busy ... a critical pillar of health, essential to not only living ...
(Date:10/1/2014)... 1, 2014 Trovagene, Inc., (NASDAQ:  TROV) ... that Eli Diamond , MD, Assistant Attending ... presented clinical data from an ongoing study demonstrating ... for the determination of oncogene mutational status in ... results were presented to both treating physicians and ...
(Date:10/1/2014)... 2014  Express Scripts (NASDAQ: ESRX ) ... Scripts Medicare ® Prescription Drug Plans (PDP) will ... WAG ) (NASDAQ: WAG ), ... support  for their Medicare dollars. Medicare beneficiaries ... or Choice plans for 2015 can ...
Breaking Medicine Technology:ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4
... NEW YORK, Feb. 6, 2012 ... market research report is available ... Commercializing Angiogenesis Affecting ... Route to Consider Your Options ...
... Reportlinker.com announces that a new market research ... , World Market for Anti-Infectives (Antifungals, ... http://www.reportlinker.com/p0769020/World-Market-for-Anti-Infectives-Antifungals-Antibacterials-and-Antivirals- .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... World Market for Anti-Infectives - focuses ...
Cached Medicine Technology:Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 2Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 3Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 4Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 5Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 6Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 7Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 8Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 9Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 10Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 11Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 12Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 13Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 14Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 15Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 16Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 17Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 18Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 19World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 2World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 3World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 4World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 5World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 6World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 7World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 8World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 9
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: